Trade Fulcrum Therapeutics Inc - FULC CFD

Fulcrum Therapeutics, Inc. Company profile

About Fulcrum Therapeutics Inc

Fulcrum Therapeutics, Inc. clinical-stage biopharmaceutical company. The Company focuses on improving the lives of patients with genetically defined rare diseases. The Company have developed a product engine which identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The Company is also engaged in developing drugs for the treatment for the root cause of muscle disorders, central nervous system disorders and blood disorders. The Company is using Its proprietary product engine to identify and validate drug targets and develop product candidates to address diseases caused by the mis-expression of certain genes. Its product candidate includes losmapimod, is a small molecule that is developed for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, is a small molecule designed to bind embryonic ectoderm development (EED).

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Fulcrum Therapeutics Inc revenues increased from $8.8M to $19.2M. Net loss increased 14% to $80.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase of 17% to $65.2M (expense), General and administrative increase of 37% to $23.9M (expense).